biotech Value proposition
Disrupting Healthcare - De-risking Innovation - Transforming Technologies
BIOASTER Technology Research Institute (TRI) is working to develop an unique technological and innovative model to support the latest challenges in microbiology, in particular to :
-Fight antimicrobials resistance.
-Improve vaccines safety and efficacy.
-Quickly diagnose infections at patient bedside.
-take full advantage to human and animal microbiota.
In order to overcome technological bottlenecks and explore new avenues, BIOASTER is leading collaborative projects that bring together academics, start-ups, SMEs and industrial groups around key thematic and technology units.
Each project strives on academic research excellence and is undertaken by a team of high-level experts and engineers, which benefits from state-of-the-art equipment, technological infrastructures.
BIOASTER, an independent non-profit organization, is one of 8 French TRIs created in 2012 on the initiative of the French Government through the “Investments for the Future” program. The two historical founders are Lyonbiopôle (a biocluster, the one-stop shop for healthcare innovation in Rhône-Alpes, France) and the Institut Pasteur in Paris. They were joined from the beginning by the CNRS, the INSERM, the CEA, Mérieux Institute, Danone Nutricia Research and Sanofi Pasteur -and newly joined by bioMérieux- to create a unique Technology Institute dedicated to infectious diseases and microbiology in health. The Institute benefits from the support of Lyon Métropole and the Region Auvergne Rhône Alpes and the dynamism of a group of 40 SMEs in the Lyon and Paris regions.
Located in Lyon and Paris, BIOASTER has more than 100 employees including 80 world-class scientists and engineers originating from 16 different countries.
More information on www.bioaster.org
Biotechnology, Infectious diseases, Microbiota, Vaccines, Antimicrobials, Diagnostic, and MicrobiologyOriginal language
Disrupting Healthcare - De-risking Innovation - Transforming Technologies
BIOASTER Technology Research Institute (TRI) is working to develop an unique technological and innovative model to support the latest challenges in microbiology, in particular to :
-Fight antimicrobials resistance.
-Improve vaccines safety and efficacy.
-Quickly diagnose infections at patient bedside.
-take full advantage to human and animal microbiota.
In order to overcome technological bottlenecks and explore new avenues, BIOASTER is leading collaborative projects that bring together academics, start-ups, SMEs and industrial groups around key thematic and technology units.
Each project strives on academic research excellence and is undertaken by a team of high-level experts and engineers, which benefits from state-of-the-art equipment, technological infrastructures.
BIOASTER, an independent non-profit organization, is one of 8 French TRIs created in 2012 on the initiative of the French Government through the “Investments for the Future” program. The two historical founders are Lyonbiopôle (a biocluster, the one-stop shop for healthcare innovation in Rhône-Alpes, France) and the Institut Pasteur in Paris. They were joined from the beginning by the CNRS, the INSERM, the CEA, Mérieux Institute, Danone Nutricia Research and Sanofi Pasteur -and newly joined by bioMérieux- to create a unique Technology Institute dedicated to infectious diseases and microbiology in health. The Institute benefits from the support of Lyon Métropole and the Region Auvergne Rhône Alpes and the dynamism of a group of 40 SMEs in the Lyon and Paris regions.
Located in Lyon and Paris, BIOASTER has more than 100 employees including 80 world-class scientists and engineers originating from 16 different countries.
More information on www.bioaster.org
BIOASTER - The first Institute for technological innovation
BIOASTER Technology Research Institute is working to develop an unique technological and innovative model to support the latest challenges in microbiology.
https://www.bioaster.org/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 IRT SystemX Research, Research Services | IRT SystemX Research, Research Services | Other 22 Nov 2023 | | |
 bioMérieux Biotechnology, Biotechnology Research | bioMérieux Biotechnology, Biotechnology Research | Other 8 Dec 2023 | | |
 Boehringer Ingelheim Pharmaceutical, Pharmaceutical Manufacturing, Animal Health | Boehringer Ingelheim Pharmaceutical, Pharmaceutical Manufacturing, Animal Health | Other 8 Dec 2023 | | |
 Auvergne-Rhône-Alpes Entreprises National and local authorities, Business Consulting and Services | Auvergne-Rhône-Alpes Entreprises National and local authorities, Business Consulting and Services | Other 8 Dec 2023 | | |
 Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 18 Mar 2024 | | |
 grandlyon National and local authorities, Government Administration, French metropolis | grandlyon National and local authorities, Government Administration, French metropolis | Other 26 Mar 2024 | | |
 CMS Francis Lefebvre Avocats Law Practice | CMS Francis Lefebvre Avocats Law Practice | Other 26 Mar 2024 | | |
 CIC Bank, Banking | CIC Bank, Banking | Other 26 Mar 2024 | | |
 Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Other 29 Mar 2024 | | |
 Pouss@LYS Financial Services | Pouss@LYS Financial Services | Other 19 Apr 2024 | | |